1 citations
,
July 2021 in “Frontiers in Oncology” Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
March 2025 in “Future Oncology” Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
7 citations
,
September 2024 in “Journal of Comparative Effectiveness Research” Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.